Kornimate/medical-research-clean huggingface dataset:
effect of irbesartan on endothelial function of the retinal vasculature in patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the retinal vasculature is morphologically and functionally related to the cerebral vessels due to its common origin from the internal carotid artery. a recent study demonstrated that endothelium-dependent vasodilation of the retinal vasculature is impaired in patients with essential hypertension, which is a strong risk factor for stroke. furthermore, at1-receptor blockade was demonstrated to improve retinal endothelium-dependent vasodilation in these hypertensive patients. hypercholesterolemia is also a risk factor for ischemic stroke and impairment of endothelial function has been observed in various vascular beds in hypercholesterolemic patients, including the coronary and the forearm vasculature. whether endothelial function of the retinal vasculature is impaired in patients with hypercholesterolemia has not yet been investigated. in patients with stroke, at1-receptor blockade and angiotensin-converting enzyme inhibition have beneficial effects on clinical outcome. alterations of endothelial function of the cerebral vasculature might be one pathogenetic factor for the beneficial clinical outcome. to further address this issue, the present study was designed to test the hypothesis that endothelium-dependent vasodilation of the retinal vasculature is impaired in hypercholesterolemic patients and that endothelial function can be improved by at1-receptor blockade.

see above

Eligibility criteria:
inclusion criteria: * male patients aged 18-65 years with ldl-cholesterol \>= 130mg/dl * male healthy control subjects aged 18-65 years exclusion criteria: * all kinds of secondary hyperlipidemia. * advanced damage of vital organs (grades iii and iv retinopathy) * lipid-lowering drugs (including lipid lowering dietary supplements or food additives) within the last 4 weeks * history of serious hypersensitivity reaction to at1-receptor blockers * actual or anamnestic alcohol- or drug abuse. * smokers or ex-smokers \< 1 year. * patients with diabetes mellitus (oral medication or insulin). * patients with arterial fibrillation or av-block (ii° or more). * patients with anamnestic myocardial infarction. * patients with instable angina pectoris including ecg-aberrations or cardiac insufficiency nyha iii or iv. * history of malignancy (unless a documented disease-free period exceeding 10 years is present) with the exception of basal cell carcinoma of the skin * history of allograft transplantation * patients with anaphylaxis or known therapy resistance of the used test matters * therapy with not approved concomitant medication, or participation in a clinical study within 4 weeks preceding treatment start. * disease which interfere with the pharmacodynamics and pharmacokinetics of the study drug. * liver or kidney disease with sgot, gpt, g-gt, ap, bilirubin and creatinin above 200% of standard. * patients, who are not sufficiently compliant, or patients, who are not capable or willing to appear for controlling visits. * presumed risk of transmission of hiv or hepatitis via blood from the proband
home high flow oxygen to reduce acute exacerbation of copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the objective of the study is to evaluate the efficacy of home high flow oxygen for the reduction of severe exacerbation following admission for a severe exacerbation of copd or death against standard oxygen therapy.


Eligibility criteria:
inclusion criteria: 1. patient with a diagnosis of copd defined by gold guidelines 2. admitted in hospital for aecopd 3. with severe respiratory impairment defined by one of the following criteria (long-term oxygen therapy (ltot) criteria): * previously established on long-term oxygen therapy according to the following criteria: pao2 \< 7.3kpa or \<8kpa with polycythemia, pulmonary hypertension or right heart failure on room air in stable condition or * pao2 \< 7.3kpa or \<8kpa with polycythemia, pulmonary hypertension or right heart failure on room air after clinical stabilization during the index admission 4. patients affiliated or, beneficiary of a social security cover 5. patient who has read and understood the information letter and signed the consent form 6. for woman of childbearing potential, use of an effective contraception (oestro-progestatives or intra-uterine device or tubal ligation) since at least 1 month and an blood pregnancy test by β-hcg negative at the screening visit, during the duration of the study 7. for menopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit) exclusion criteria: 1. age \ 85 years 2. patient treated with chronic niv with ongoing treatment 3. patients diagnosed with obstructive sleep apnea (osa) treated with cpap. diagnosis of osa will be over-ruled in patient that had a previous overnight polygraphy. for patients who never had an overnight polygraphy, screening for osa will be made using the stop-bang questionnaire. if the results of the stop-bang questionnaire (appendix 1) is \>3, an apnea-link recording will be performed. if ahi\>30/h, patient will be excluded. 4. bmi \> 35 kg/m2 5. patient admitted for an acute covid-19 infection 6. hypercapnic respiratory failure justifying niv defined as 1. an arterial blood gas (abg) paco2 \> 7 kpa in stable condition within 6 months 2. patients with abg paco2 \> 7 kpa at hospital discharge and that remained hypercapnic between 2- and 4-weeks following discharge 7. pregnancy (blood pregnancy test positive) or lactation ongoing 8. significant psychiatric disorder or dementia that would prevent adherence to study protocol 9. tobacco use \< 10 pack-year 10. expected survival \< 12 months due to any situation other than copd disease 11. refusal of high-flow oxygen therapy 12. person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision) 13. patients already involved in a research protocol that would impact with the outcome measured in the current protocol
benchmarking outcomes in pancreatic surgery - whipplebenchmarks.org

Conditions: Pancreatic Neoplasms; Pancreaticoduodenectomy

Summary: the whipplebenchmark 2 collaborative study aims at defining benchmark criteria for best achievable outcomes after pancreaticoduodenectomy with portal vein resection.

pancreatoduodenectomy (pd) with portal vein resection (pvr) is performed for the achievement of complete resection (r0) in patients with locally advanced pancreatic head lesions. despite most commonly performed in high-volume pancreatic surgery centers by experienced surgeons, best achievable outcomes, such as morbidity and mortality, following such complex procedure remain unknown. the aim is to conduct a retrospective multicenter cohort study to define benchmark values for best achievable outcomes following duodenopancreatectomy (dp) with portal vein resection (pvr). data collection and study design are based on to the well established standardized reporting for benchmarking (sánchez-velázquez et. al. ann surg, february 2019 ). this multicenter cohort study will include all consecutive pancreaticoduodenectomies with portal vein resections from at least 20 high volume centers performing over 50 pancreatic operations per year or 150 cases within 3 years from at least 3 continents over a period of 10 years (2009-2019). every center included in the study must have a prospective database from which data can be collected as well as previous publications critically reporting on their outcome.

Eligibility criteria:
center eligibility criteria * high volume centers from ≥3 continents * minimum 50 cases of pancreatic surgery per year or 150 cases within 3 years * published in the area of pancreas surgery * prospective database available patient eligibility criteria inclusion criteria: * adults ≥ 18 years * resectable malignant or benign diseases (i.e. all indications) * open pancreaticoduodenectomy (all techniques allowed) with concurrent portal vein resection exclusion criteria: * patients \< 18 years * pancreatic resections other than pancreaticoduodenectomy and portal vein resection * pancreaticoduodenectomy with arterial reconstruction * laparoscopic or robotic pancreaticoduodenectomy

Keywords: pancreaticoduodenectomy portal vein resection benchmarks outcomes
intensive therapy archival research

Conditions: Trauma, Psychological

Summary: this is an internal treatment evaluation to determine whether eye movement desensitization and reprocessing (emdr) or progressive counting (pc) should become the preferred trauma treatment for the investigator's clients. the investigator is using routine/existing in-house measures and case files to track symptom reduction, trauma treatment time, rate of treatment switching (from emdr to pc or vice versa), and rate of trauma treatment refusal. this is retrospective as well as prospective archival research.


Eligibility criteria:
inclusion criteria: * victims of crimes, including assault, rape, robbery, intimate partner violence, child abuse, kidnapping, vehicular homicide, and suicide * witnesses and family members of victims
narrative exposure therapy versus group interpersonal psychotherapy

Conditions: Posttraumatic Stress Disorder; Depression; Narrative Exposure Therapy; Interpersonal Psychotherapy

Summary: the present study is a pragmatic trial that investigates the efficacy and usefulness of two treatment modules in a sample of rwandan genocide orphans: narrative exposure therapy (net) versus group-interpersonal psychotherapy (ipt). we used a half year baseline to measure the treatment-induced changes. we hypothesized that there would be a greater reduction in posttraumatic stress symptoms in the net- than in the ipt-group and that ipt would be superior to net in the reduction of depression symptoms.

the 1994 genocide of rwanda has left countless children orphaned. 26 rwandan orphans who fulfilled dsm-iv diagnosis of ptsd were offered participation in a controlled treatment trial. a group adaptation of interpersonal psychotherapy (ipt, n = 14) was compared to narrative exposure therapy (net, n = 12). main outcome measures were symptoms of ptsd and depression assessed pre-treatment, 3 months after therapy (post-test) and 6 months after therapy (follow-up) using the caps, mini and hamilton rating scale. at post-test, participants in both treatment conditions showed reductions in posttraumatic stress symptoms and depression symptoms. at 6-month follow-up, net proved to be more effective in the treatment of ptsd. only 25% (n = 3) of net-participants but 71% (n = 10) of the ipt-participants still fulfilled ptsd criteria at follow-up. although there was a significant reduction in depression symptoms in both treatment groups from pre-test to follow-up, net again proved to be more effective. this treatment-trial demonstrates that net and group-ipt are suitable treatment modules even when most severe traumatic stress and difficult living conditions have led to chronic mental suffering.

Eligibility criteria:
inclusion criteria: * rwandan orphans who have experienced the genocide, who lost at least one parent during the genocide and who were no older than 18 years during the genocide exclusion criteria: * mental retardation * psychotic symptoms or current drug or alcohol

Keywords: posttraumatic stress disorder depression narrative exposure therapy interpersonal psychotherapy
liraglutide for hiv-associated neurocognitive disorder

Conditions: HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome

Summary: this study will test the effect of liraglutide on cognitive function in hiv-infected overweight or obese subjects with type 2 diabetes.

hiv, insulin resistance and type 2 diabetes mellitus (dm) are independently associated with cognitive impairment. considering the synergistic effects of hiv and dm on cognition, these subjects are at increased risk of cognitive impairment. glucagon-like peptide 1 (glp-1) receptors have wide tissue distribution including the central nervous system. the study hypothesis is that glp-1 could potentially ameliorate the impairments in cognition in this population. this study will assess the impact of liraglutide on neurocognitive performance and peripheral inflammatory markers. it will also evaluate the effects of liraglutide on glycemic control and metabolic risk factors in hiv infected subjects with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * hiv controlled on therapy for at least 12 weeks * viral load \< 200 copies * bmi \>27 to 45 * diagnosis of dm type 2 with a1-c \>7 to 15 * participants must be willing to comply with all study related procedures exclusion criteria: * personal or family history of pancreatitis * medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men 2) * gastroparesis * allergy to liraglutide or any of the active ingredients in liraglutide or other glp-1 analogue * weight loss drugs other than metformin * type 1 diabetes mellitus or diabetic ketoacidosis * known major cognitive deficit dementia, history of head trauma with loss of consciousness \>30 min, history of stroke, current central nervous system (cns) disorder such as seizures or opportunistic cns infection * renal insufficiency defined as creatinine clearance \< 60 ml/min * active opportunistic infections * pregnancy or breastfeeding * unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome * decompensated heart failure * substance abuse * active alcohol or opioid substitution therapy * serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation

Keywords: hiv infection diabetes mellitus type 2 obesity neurocognitive function
long-term effects of aortic valve mismatch

Conditions: THE LEFT VENTRICULAR REMODELING AFTER MECHANICAL AORTIC VALVE REPLACEMENT

Summary: the real impact of the existence of an aortic valve mismatch after aortic valve replacement in various studies conducted so far is a source of controversy. there is currently no long-term impact of the aortic valve mismatch on the reversal of left ventricular remodeling and its impact functional.to evaluate these effects of aortic valve mismatch on abilities to the effort, the quality of life and the regression of left ventricular hypertrophy long term after a aortic valve replacement, conducting a new study is fundamental. this study is even more essential in patients with a young life expectancy theoretical long and physical activity.our study aims to determine whether the existence of an aortic valve mismatch has an influence on: the functional capacity to the effort by measuring the maximum oxygen consumption during a stress test (vo2 max) the reversal of left ventricular remodeling (cardiac ultrasound doppler), diastolic dysfunction (cardiac ultrasound and doppler measurement brain natriuretic peptide (bnp). this study will analyse these data in patients who received youth a van by mechanical aortic valve prosthesis.


Eligibility criteria:
inclusion criteria: * patient major ≤ 60 years at the time of the aortic valve replacement. * patient affiliated with a social security * consent dated and signed by the investigator and the subject * subject having been informed of the results of the visit prior aortic valve replacement by mechanical prosthesis for pure aortic narrowing. * fraction left ventricular ejection ≥ 50%, when aortic valve replacement and at the time of inclusion. * aortic insufficiency at aortic valve replacement associated \<ii / iv. * aortic valve replacement exclusive (no gestures associated: coronary bypass, enlargement of the ring, another valve surgery,...). * coronarography normal at the aortic valve replacement. * normal renal function. * no history of heart failure episode in the previous month inclusion. * no indication against a stress test on bicycle ergometric exclusion criteria: * refusal of the patient to be included in the study. * history of cardiac surgery under extra body movement before and / or after the aortic valve replacement. * aortic insufficiency associated with the time of the transaction\> ii / iv. * chronic respiratory insufficiency. * track cancer or cancer evolving. * evolutionary osteoarthritis of the lower limbs or widespread. * myopathy device. * alteration higher making it impossible to carry out the test effort and response to the questionnaire on the quality of life. * coronaropathy documented.

Keywords: the left ventricular remodeling after mechanical aortic valve replacement exercise training
online cognitive rehabilitation of executive dysfunction in nonamnestic mci

Conditions: Nonamnestic Mild Cognitive Impairment; Cognitive Dysfunction; Cognitive Disorder; Neurocognitive Disorders; Mental Disorder; Cognitive Impairment, Mild

Summary: nonamnestic mild cognitive impairment (namci) is a prodromal state characterized by deficits in executive functioning, a collection of higher-order abilities involved in organization, planning, inhibition, and complex reasoning. research shows that individuals with namci have an increased risk of developing non-alzheimer's dementia such as frontotemporal dementia and dementia with lewy bodies, which pose substantial personal and societal costs. accordingly, interventions that can successfully slow down or reverse the course of namci are needed. goal management training (gmt) is a cognitive rehabilitation platform that has been studied extensively, applied clinically, and manualized into kits for clinicians (levine et al., 2000; levine et al., 2007; levine et al., 2011; stamenova \& levine, 2019). the purpose of gmt is to train individuals to periodically "stop" what they are doing, attend to task goals, evaluate their performance, and monitor or check outcomes as they proceed. recently, an online version of gmt has been developed and validated in order to circumvent barriers to attending in-person sessions. the purpose of the current study is to determine if the online version of gmt is effective at improving self-reported executive dysfunction in individuals diagnosed with namci against a control group that is receiving treatment-as-usual from their care provider. it is hypothesized that, compared to the control group, individuals receiving gmt will report a decrease in executive function deficits.


Eligibility criteria:
inclusion criteria: * diagnosis of nonamnestic mild cognitive impairment * available to participate in all testing and intervention sessions * access to a computer * computer familiarity * normal or corrected-to-normal vision and hearing exclusion criteria: * diagnosis of amnestic mild cognitive impairment or dementia * moderate to severe affective impairment defined by score above cut-off for depression on the patient health questionnaire-9 (phq-9; kroenke et al., 2001)

Keywords: nonamnestic mci executive functions online cognitive intervention online cognitive rehabilitation
acupuncture for lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: the clinical trial aims to evaluate the efficacy and safety of acupuncture in alleviating neurogenic claudication symptoms among patients with degenerative lumbar spinal stenosis (lss).


Eligibility criteria:
inclusion criteria: 1. meet the diagnosis criteria of lss; 2. aged between 50-80 years; 3. neurogenic claudication (nc) for more than 3 months; 4. able to walk for at least 20 meters continually without device assistance, and forced to stopped walking out of nc within 30 mins in the meanwhile; 5. the average pain of buttocks and/or legs scores≥4 on the numerical rating scale (nrs) when walking, standing, or extending the back in the past week; 6. more severe pain in the buttock and/or leg than in the lower back; 7. score at least 7 on modified roland-morris disability questionnaire（rmdq）; 8. central sagittal diameter stenosis of lumbar spinal canal as manifested by mri or ct scan; 9. volunteer to participate the trial and provide written informed consent. exclusion criteria: 1. non-degenerative lss, such as congenital, post-traumatic or spondylolisthesis lss; operation indications, such as segmental muscular atrophy, bowel and bladder disfunction, and spinal instability; tuberculosis or tumor in the lumbar area; or multiple vertebral compression fracture or compression fracture in the segment of stenosis; 2. vascular claudication; 3. severe heart, pulmonary, liver and/or kidney diseases; 4. clinical comorbidities that may interfere with the assessment of pain intensity or walking ability, such as fibromyalgia, chronic widespread pain, amputation, stroke, parkinson's disease, spinal cord injury, severe diabetes, and severe hypertension etc; 5. unable to complete motorized treadmill test at the speed of 2km/h; 6. severe psychiatric disorder or cognitive impairment that prevent the understanding of the outcome evaluating questionnaires; 7. a history of lumbar surgery; 8. have received acupuncture treatments in the previous 2 weeks;

Keywords: acupuncture neurogenic claudication randomized controlled trial lumbar spinal stenosis
relationship between left ventricular remodeling, coronary endothelial function and myocardial fibrosis using positron emission tomography in patients with st-elevation myocardial infarction

Conditions: ST Elevation Myocardial Infarction

Summary: left ventricular remodeling is a common complication in patients with st-elevation myocardial infarction (stemi ) and may lead to heart failure. hemodynamic, metabolic and inflammatory mechanisms are involved in this pathophysiological process. recent data demonstrated that remote, noninfarct-related region of the myocardium is also implicated. there is no data about the assessment of coronary endothelial function or myocardial fibrosis in the remote zone in patients with stemi . the correlation between these parameters and left ventricular remodeling is not known.


Eligibility criteria:
inclusion criteria: * first st elevation myocardial infarction * primary percutaneous coronary intervention (timi 3) * single vessel coronary artery disease * age over 18 years * informed consent dated and signed * written and spoken french * beneficiary of social security insurance exclusion criteria: * no primary percutaneous coronary intervention * timi 0-2 after primary percutaneous coronary intervention * significant two or three-vessel coronary artery disease (\> 70% stenosis in at least one of the other two coronary arteries) * past history of myocardial infarction before stemi * mechanical complication (ischaemic mitral regurgitation, interventricular septal defect, cardiac tamponade) or clinical signs of heart failure * pregnant and / or lactating * age under 18 years or guardianship

Keywords: st elevation myocardial infarction ventricular remodeling biomarkers coronary endothelial function positron emission tomography